Market
What will be the most significant challenge in the third set of teeth drug trials by end of 2025?
2
Resolution / Starting Odds
Safety concerns • 25%
Efficacy issues • 25%
Regulatory hurdles • 25%
Other • 25%
Reports and publications by the research team or scientific journals
Story
Japanese Researchers Test Drug to Regrow Third Set of Teeth, Targeting USAG-1 Protein in Clinical Trials
Dec 13, 2024, 01:30 PM
Japanese researchers are conducting clinical trials on a pioneering drug designed to stimulate the growth of a third set of teeth, which could provide a natural alternative to dentures and implants. The drug targets the USAG-1 protein and utilizes RNA technology to promote tooth regeneration. This development is significant as it challenges the long-held belief that humans and most mammals only grow two sets of teeth. Additionally, a study has identified 18 genomic regions linked to tooth shape and size, including a gene inherited from Neanderthals that influences these characteristics. The research is led by Katsu Takahashi at a medical research facility in Japan.
View original story
Similar markets
No tooth regrowth • 25%
Moderate tooth regrowth • 25%
Significant tooth regrowth • 25%
Minimal tooth regrowth • 25%
Gum irritation • 25%
No significant side effects • 25%
Mild discomfort • 25%
Severe pain • 25%
Vaccine efficacy data • 25%
Regulatory approval process • 25%
Trial participant demographics • 25%
Adverse side effects • 25%
Phase 1 completion • 25%
No significant milestone • 25%
Phase 3 completion • 25%
Phase 2 completion • 25%
Unsuccessful • 25%
Trial inconclusive • 25%
Successful with high efficacy • 25%
Successful with moderate efficacy • 25%
Significant improvement • 25%
Worse outcomes • 25%
No improvement • 25%
Moderate improvement • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
Positive efficacy and safety results • 25%
Negative efficacy, but good safety • 25%
Negative efficacy and safety concerns • 25%
Positive efficacy, but safety concerns • 25%